Findings

What do systematic reviews say?

4,815 questions · 6,211 findings · 638 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,052 · 16.9%GRADE not reported 441 · 7.1%Very low 1,700 · 27.4%Low 1,651 · 26.6%Moderate 1,070 · 17.2%High 297 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

McKenzie therapy vs other interventions

Adverse events · patients with non‐specific acute and subacute low back pain

The review found no eligible studies for this question.

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

McKenzie therapy vs minimal intervention

Pain: intermediate‐term · patients with non‐specific acute and subacute low back pain

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 180 participants
Low

McKenzie therapy vs minimal intervention

Disability 1 week (immediate term) (RMDQ 0 to 24) · patients with non‐specific acute and subacute low back pain

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 328 participants
Low

McKenzie therapy vs minimal intervention

Disability (intermediate‐term) RMDQ. Scale from: 0 to 24. · patients with non‐specific acute and subacute low back pain

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 180 participants
Low

McKenzie therapy vs minimal intervention

Adverse events · patients with non‐specific acute and subacute low back pain

The review found no eligible studies for this question.

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

McKenzie therapy vs manual therapy

Pain intensity various scales short‐term · patients with non‐specific acute and subacute low back pain

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 298 participants
Low

McKenzie therapy vs manual therapy

Pain: intermediate‐term · patients with non‐specific acute and subacute low back pain

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 235 participants
Low

McKenzie therapy vs manual therapy

Disability Multiple scales (0 to 100) Short‐term · patients with non‐specific acute and subacute low back pain

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 298 participants
Low

McKenzie therapy vs manual therapy

Disability (intermediate‐term) RMDQ. Scale from: 0 to 24. · patients with non‐specific acute and subacute low back pain

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 235 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(1885) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 3776 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(407) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 234 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(1512) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1012 participants
Very low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1012 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(3774) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 4088 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 4118 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(3044) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3207 participants
Moderate
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3207 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(1935) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1294 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1294 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(543) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 404 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 404 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(4360) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2278 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2278 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(1941) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1334 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1334 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(295) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1153 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1153 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(354) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 243 participants
Very low